Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension
Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension. // American Journal of Preventive Cardiology. – URL: https://www.sciencedirect.com/science/article/pii/S2666667726003570?dgcid=rss_sd_all
Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension. American Journal of Preventive Cardiology. https://www.sciencedirect.com/science/article/pii/S2666667726003570?dgcid=rss_sd_all
“Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension.” American Journal of Preventive Cardiology.
@article{article34943,
title = {Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension},
journal = {American Journal of Preventive Cardiology},
url = {https://www.sciencedirect.com/science/article/pii/S2666667726003570?dgcid=rss_sd_all}
}